Navigation Links
Common Epilepsy Drug Taken During Pregnancy Might Raise Spina Bifida Risk
Date:12/3/2010

By Steven Reinberg
HealthDay Reporter

FRIDAY, Dec. 3 (HealthDay News) -- Pregnant women with epilepsy who are taking carbamazepine (Tegretol) to control seizures may be at a slightly increased risk of having an infant with spina bifida, a new study finds.

Spina bifida is a condition in which the bones of the spine do not close but the spinal cord remains in place, usually with skin covering the defect. Most children will need lifelong treatment for problems arising from damage to the spinal cord and spinal nerves.

"For women with epilepsy, seizure control during pregnancy is very important," said lead researcher Lolkje de Jong-van den Berg, from the division of pharmacy at the University of Groningen in the Netherlands. "Our study can help in decisions regarding whether carbamazepine should be the drug of choice in pregnancy."

However, the best option regarding treatment can be chosen only on an individual basis by the woman and her neurologist before pregnancy, weighing the benefits of epilepsy control against the risk of birth defects, de Jong-van den Berg said.

The report is published in the Dec. 3 online edition of the BMJ.

For the study, de Jong-van den Berg's team reviewed existing research to determine the risk of birth defects among women taking Tegretol.

The researchers found that infants of women taking Tegretol were 2.6 times more likely to have spina bifida, compared with women not taking any anti-epileptic medication.

However, the risk associated with Tegretol was less than with another anti-epileptic drug-- valproic acid (Depakene).

In fact, Tegretol was less risky than valproic acid when it came to other birth defects such as hypospadias, where a boy's urinary opening develops in the wrong part of the penis or in the scrotum.

"Carbamazepine is specifically related to an increased risk of spina bifida," de Jong-van den Berg said. "But you have to keep in mind that the absolute risk is small."

For Tegretol taken in the first trimester, the overall risk of a major malformation was 3.3 percent, the study authors reported.

The same group of researchers found in another study, published this year in the New England Journal of Medicine, that women taking valproic acid were six times more likely to have an infant with spina bifida and seven times more likely have an infant with hypospadias, compared with women using other anti-epileptic drugs.

The researchers agree with a recommendation from the American Academy of Neurology that valproic acid should be avoided in pregnancy if possible.

Dr. Orrin Devinsky, director of the Epilepsy Center at NYU Langone Medical Center, said that "for women of childbearing age, these drugs represent a risk."

Women need to balance the risk and benefit of these drugs, he explained. Women with epilepsy need to stay on an anti-epileptic drug while they are pregnant, Devinsky said.

"The risk of seizure to themselves and potentially to their fetus is greater than the risk of anti-epileptic drugs," he added.

There are alternative drugs, specifically lamotrigine (Lamictal) and levetiracetam (Keppra). However, there is little data on any dangers associated with these drugs during pregnancy, Devinsky noted.

Another expert, Dr. Kimford Meador, a professor of neurology at Emory University School of Medicine, said women need to know the risks associated with Tegretol.

"If a woman is of childbearing potential and you are prescribing this drug, that's when the conversation needs to occur," Meador said.

More information

For more information on epilepsy, visit the U.S. National Library of Medicine.

SOURCES: Lolkje de Jong-van den Berg, Ph.D., Pharm.D., Division of Pharmacy, University of Groningen, the Netherlands; Orrin Devinsky M.D., director, Epilepsy Center, NYU Langone Medical Center, and professor, neurology, neurosurgery and psychiatry, New York University School of Medicine, New York City; Kimford Meador, M.D., professor, neurology, Emory University School of Medicine, Atlanta; Dec. 3, 2010, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Epilepsy Drug Taken During Pregnancy Might Raise Spina Bifida Risk
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... named the 2017 North American CAREGiverSM of the Year for her extraordinary compassion ... one of its 60,000 North American professional caregivers for the prestigious award each ...
(Date:4/27/2017)... ... 27, 2017 , ... Offering the purest product of its kind, Swissx Labs ... more potent than the market has seen before. Swissx uses proprietary strains of hemp ... patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits for health ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., ... announced it has completed a round of funding to accelerate its growth strategies. ... Black Granite Capital is a growth equity firm focused on investments in healthcare ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... is thrilled to announce the ATA 2017 President’s Awards recipients, comprised of ... demonstrated superior healthcare delivery. , The ATA 2017 President’s Awards recognize ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
Breaking Medicine Technology: